The Reversibility of Cardiac Neuronal Function After Removal of a Pheochromocytoma
- 1 July 1999
- journal article
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 24 (7) , 514-518
- https://doi.org/10.1097/00003072-199907000-00009
Abstract
Twelve patients with proved pheochromocytoma evaluated in our institution between 1991 and 1997 are described. The patients' urinary excretion rates and their metabolites (vanylmandelic acid and metanephrines) were significantly greater than normal before surgery. Echocardiography showed normal left ventricular ejection fractions (72% +/- 8%). All of the patients underwent planar I-123 metaiodobenzylguanidine (MIBG) scintigraphy to assess cardiac neuronal uptake 4 hours after and locate a pheochromocytoma 24 hours after intravenous injection of 185 MBq (3 mCi) I-231 MIBG. Ten patients with pheochromocytoma had positive tumoral findings with I-123 MIBG scintigraphy. Twelve patients had significant impairment of cardiac neuronal uptake of MIBG, with a heart:mediastinum ratio averaging 142% +/- 18% (normal value, 230% +/- 30%, P < 0.05). Postoperative cardiac MIBG imaging was performed in all patients (at 6 +/- 3 months). After surgical removal of the pheochromocytoma, cardiac MIBG uptake and the heart:mediastinum uptake ratios improved significantly (197% +/- 20%, P < 0.05) in all the patients. Urinary excretion rates and metabolites returned to the normal range. However, no significant correlation was found between cardiac MIBG uptake and urinary excretion rates and metabolites after the tumors were removed. Removing a pheochromocytoma reversed cardiac neuronal function as assessed by MIBG scintigraphy.Keywords
This publication has 10 references indexed in Scilit:
- Inotropic responsiveness of the heart in catecholamine cardiomyopathyPublished by Elsevier ,2004
- Impact of exercise rehabilitation on cardiac neuronal function in heart failure: an iodine-123 metaiodobenzylguanidine scintigraphy studyEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Abnormal myocardial uptake and clearance of 123I-labeled metaiodobenzylguanidine in patients with chronic renal failure and autonomic dysfunctionJournal of Nuclear Cardiology, 1996
- Pheochromocytoma with catecholamine-induced impairment of cardiac neuronal functionAmerican Heart Journal, 1995
- Noninvasive Detection of Cardiac Sympathetic Nervous Dysfunction in Diabetic Patients Using [123I]MetaiodobenzylguanidineDiabetes, 1992
- Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I]metaiodobenzylguanidineDiabetes, 1992
- Reversible catecholamine-induced cardiomyopathyAmerican Heart Journal, 1991
- Phaeochromocytoma and catecholamine induced cardiomyopathy presenting as heart failure.Heart, 1990
- Iodine-123 meta-iodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathyJournal of the American College of Cardiology, 1988
- Coronary vasoconstriction and catecholamine cardiomyopathyAmerican Heart Journal, 1985